Hof Danielle, von Eckardstein Arnold
Institut für Klinische Chemie, UniversitätsSpital, Zürich.
Ther Umsch. 2009 Apr;66(4):253-9. doi: 10.1024/0040-5930.66.4.253.
Coronary heart disease (CHD), which is caused by atherosclerosis, is the most common cause of death worldwide, and the prevention of CHD is therefore an essential clinical and public task. Classical risk factors like smoking, diabetes and hypercholesterolemia, are combined in several risk scores to estimate the risk for a cardiovascular event within the next 10 years. Despite their clinical success it is important to note that current methods have limited sensitivity and a low positive predictive value. Therefore, new biomarkers need to be identified to improve risk stratification. This review describes the pathogenesis and risk stratification of CHD, and provides an overview of the most important new biomarkers and their current applications in the prevention of CHD.
冠心病（CHD）由动脉粥样硬化引起，是全球最常见的死亡原因，因此预防冠心病是一项重要的临床和公共任务。吸烟、糖尿病和高胆固醇血症等经典风险因素被纳入多个风险评分中，以估计未来10年内发生心血管事件的风险。尽管这些方法在临床上取得了成功，但需要注意的是，目前的方法敏感性有限且阳性预测值较低。因此，需要识别新的生物标志物以改善风险分层。本综述描述了冠心病的发病机制和风险分层，并概述了最重要的新生物标志物及其在冠心病预防中的当前应用。
